Drug Profile
LDP 392
Alternative Names: CMI 392Latest Information Update: 07 May 2008
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals; University of Virginia
- Class Skin disorder therapies; Small molecules
- Mechanism of Action 5-lipoxygenase inhibitors; Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Asthma; Atopic dermatitis; Psoriasis; Skin disorders
Most Recent Events
- 22 Oct 2003 No development reported - Phase-II for Atopic dermatitis in USA (Topical)
- 22 Oct 2003 No development reported - Phase-II for Psoriasis in USA (Topical)
- 22 Oct 2003 No development reported - Preclinical for Adult respiratory distress syndrome in USA (unspecified route)